Latest News and Press Releases

Exchanged notes have fixed-price conversion of $3.00 per share, premium of 245% to the closing price on April 13, 2017;  Derivative liability eliminated SALT LAKE CITY, April 17, 2017 (GLOBE...

SALT LAKE CITY, April 12, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSND) (the “Company”), a molecular diagnostics company, announced today it has received CE Marking for its...

Exchange of securities will eliminate floorless variable-rate convertible securities;provide access to $11.6 million of gross proceeds to fund 2017 growth plans SALT LAKE CITY, April 10, 2017 ...

 Company to effect stock split on April 10, 2017Stock will trade under the temporary symbol GBSNDSALT LAKE CITY, April 07, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a...

SALT LAKE CITY, April 06, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced that a research article, “A Novel Approach to Eliminate...

SALT LAKE CITY, April 03, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, has received U.S. Food & Drug Administration (FDA) clearance for...

Company reduces operating costs, improves gross margin and cash burn rate quarter-over-quarterFourth quarter revenue increased 39% year-over-year; 2016 revenues increased 42%14% reduction in net cash...

SALT LAKE CITY, March 09, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, announced that during a special meeting of stockholders held today,...

SALT LAKE CITY, March 02, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, announced today that Dr. Suzette Chance, senior director of regulatory...

SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced the Journal of Clinical Microbiology published results...